Please try another search
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Hyam I. Levitsky | 65 | 2018 | Independent Non-Executive Director |
Christy J. Oliger | 53 | 2021 | Independent Director |
Veleka R. Peeples-Dyer | 51 | 2023 | Independent Director |
Dieter Weinand | 64 | 2018 | Lead Independent Director |
Kapil Dhingra | 65 | 2017 | Independent Director |
Joseph P. Slattery | 59 | 2017 | Independent Director |
Paolo Pucci | 63 | 2020 | Independent Director |
Philip Astley-Sparke | 53 | 2015 | Executive Chairman |
Robert Coffin | 59 | 2015 | Founder, Chief Scientist & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review